Monoclonal antibodies for AQP4-positive NMOSD
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial is testing monoclonal antibody treatments for people with a specific type of neuromyelitis optica spectrum disorder (NMOSD) caused by AQP4 antibodies. It aims to see if these targeted therapies can help control the disease and prevent relapses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have been diagnosed with NMOSD and tested positive for AQP4 antibodies in your blood or spinal fluid.
- Your neurological condition should be stable, with no major relapses in the last 30 days.
- You must agree to use effective birth control during the study and for 30 days after the last dose.
- You cannot have active infections like HIV, hepatitis B or C, tuberculosis, or certain other infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests B001 injection to see if it can help people with neuromyelitis optica spectrum disorder (NMOSD) who have had recent relapses. It may be aimed at reducing future attacks and improving disability over time.
This trial tests a new medicine (NouvSoma001) for people with neuromyelitis optica (NMOSD) who are having a flare-up. The goal is to see if the treatment is safe and if it helps reduce symptoms like pain and trouble moving.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This trial studies ofatumumab to reduce disease activity in adults with AQP4-IgG positive NMOSD who have had recent relapses. It may help lower the chance of new attacks and help prevent worsening disability over time.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
Hear when a new NMO Spectrum Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.